1. Omega-3 Prescriptions vs Supplements in Practice

3. Hypertriglyceridemia

4. Unmet Need for Adjunctive Dyslipidemia Therapy

5. Residual Risk of CV Events on Statin Therapy

6. Potential CVD Benefits

7. Areas of Interest for OM3FA

8. Suboptimal Omega-3 PUFA Consumption Among US Adults

9. Meta-Analysis of RCTs and PCSs Omega-3 PUFA and CHD Risk

10. Real-World Data Presented at ADA 2018

11. Omega-3 PUFA Supplementation and Prevention of Clinical CVD Science Advisory From the AHA

12. Dietary Supplements vs OTC Drugs vs Prescription Drugs

13. EPA + DHA Content in Dietary Supplements

14. EPA and DHA Intake Continuum of Cardioprotection

15. Potential Benefits of EPA and DHA

16. Metabolism of EPA and DHA Key Findings

17. The GISSI-Prevenzione Trial Post-MI

18. GISSI-Prevenzione Trial Results

19. JELIS EPA for Primary Prevention

20. REDUCE-IT Study Design

21. CV Outcomes Trials in Patients With Hypertriglyceridemia

22. Ongoing Clinical Trials With OM3FA

23. More Conflicting Results… Meta-Analysis of 10 Trials

24. Considerations for Evaluating Clinical Data

25. Reduction in CHD in Patients With High TG and Low HDL Demonstrated With Fibrates

26. Risk Difference vs Placebo of HTG Subgroups Primary and Secondary CVD Prevention Trials

27. Synergistic Effects With Statins

28. Allergies and Safety With Supplements

29. Multidisciplinary Team Strategies

30. Conclusion

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)